Cipla Peer Comparison

NSE: CIPLA | BSE: 500087

₹1,346.00

₹-33.30 (-2.41%)

As on 30-Sep-2026IST

Market cap

₹1,09,063 Cr

Revenue (TTM)

₹28,324 Cr

P/E Ratio

32.4

P/B Ratio

3.1

Div. Yield

1 %

Edit

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
Market cap (₹ Cr)	1,09,063	4,36,679	1,82,634	1,16,045	1,03,468
Revenue (₹ Cr)	28,324	59,911	15,723	28,592	14,738
Net Profit (₹ Cr)	3,364.84	12,172.70	2,156.00	4,492.20	2,055.11
Net Margin (%)	11.54	19.41	13.77	14.92	13.64
RoE (%)	10.63	15.65	26.88	18.78	13.60
Price to Earnings	32.36	36.10	83.74	25.71	50.65
Price-To-Book	3.10	5.05	20.35	4.30	6.15

Income Statement (₹ Cr)

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
Operating Revenue	28,324.40	59,910.52	15,723.00	28,591.70	14,737.88
Total Income	29,158.75	62,725.79	15,654.00	30,111.40	15,061.79
Total Expenditure	22,985.32	42,647.50	10,532.00	21,334.70	10,911.05
EBITDA	5,339.08	17,263.02	5,191.00	7,257.00	3,826.83
Depreciation	1,304.52	2,976.02	1,511.00	1,724.60	893.20
EBIT	4,034.56	14,287.00	3,680.00	5,532.40	2,933.63
Interest	57.37	363.78	634.00	510.20	578.61
Other Income	834.35	2,815.27	-69.00	1,519.70	323.91
Exceptional Items	-275.91	-693.57	-110.00	-534.80	-129.75
Profit before Tax	4,535.63	16,044.92	2,867.00	6,007.10	2,549.18
Provision for Tax	1,170.79	3,872.22	711.00	1,514.90	494.07
Profit after Tax	3,364.84	12,172.70	2,156.00	4,492.20	2,055.11

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
Shareholder's Funds	34,431.95	83,570.09	8,389.00	27,111.40	16,300.34
Minority Interest	14.98	-21.43	25.00	-79.70	-24.90
Non-Current Liabilities	962.15	2,283.44	18,384.00	7,112.50	5,011.23
Current Liabilities	7,013.59	22,622.04	8,343.00	15,711.90	6,507.25
Total Liabilities	42,342.71	1,08,407.20	43,613.69	50,672.60	27,754.83

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
Non-Current Assets	15,471.21	43,711.29	33,955.00	31,677.20	20,274.65
Current Assets	24,145.86	63,860.29	9,392.00	19,906.10	6,954.20
Total Assets	42,342.71	1,08,407.20	43,613.69	50,672.60	27,754.83
Total Debt*	257.97	4,081.61	14,798.24	11,769.50	6,021.78
Net Current Assets	17,132.27	41,238.25	1,049.00	4,194.20	446.95
Contingent Liabilities	987.37	1,587.05	379.25	989.90	924.77

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
Cash From Operating Activities	3,940.02	12,419.18	3,022.71	2,116.60	3,121.29
Cash Flow from Investing Activities	-2,326.13	-11,344.05	-12,712.41	-8,296.10	-196.42
Cash from Financing Activities	-1,233.65	-2,512.55	10,150.60	5,806.90	-2,952.69
Net Cash Inflow / Outflow	380.24	-1,437.42	460.90	-372.60	-27.82

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
ROCE (%)	16.00	19.11	19.27	21.39	13.24
ROE (%)	10.63	15.65	26.88	18.78	13.60
ROA (%)	8.42	12.12	7.27	10.03	7.36
EBIT Margin (%)	14.24	23.85	23.41	19.35	19.91
Net Margin (%)	11.54	19.41	13.77	14.92	13.64
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
Revenue Growth (%)	1.85	11.41	32.85	21.11	14.16
EBIT Growth (%)	-33.61	8.10	20.66	-8.99	19.45
Net Profit Growth (%)	-37.77	16.92	7.69	-3.14	8.09
EPS Growth (%)	-33.63	10.18	12.04	4.31	12.27
Book Value Growth (%)	10.59	15.72	10.51	13.19	13.74

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
Price / Earnings	30.47	34.58	71.80	23.74	48.14
Price / Book Value	3.10	5.05	20.35	4.30	6.15
Dividend Yield (%)	0.96	0.88	0.79	0.09	0.04
EV/EBITDA	18.79	23.65	37.64	16.62	28.08
Market Cap (₹ Cr)	98,797.18	4,21,639.92	1,42,851.87	87,643.18	82,801.75

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
Debt to Equity	0.00	0.00	1.39	0.12	0.17
Short term debt to equity ratio	0.00	0.05	0.35	0.16	0.04
Current Ratio	3.44	2.82	1.13	1.27	1.07
Quick Ratio	2.50	2.31	0.75	0.91	0.74
Interest Coverage	80.06	45.11	5.52	12.77	5.41

	Cipla	Sun Pharmaceutical	Torrent Pharma	Zydus Lifesciences	Mankind Pharma
Debtors to sales (%)	19.84	25.89	19.28	18.94	11.74
Asset Turnover	0.71	0.60	0.53	0.64	0.53
Receivable days	52.05	89.14	45.41	33.55	39.93
Inventory Days	57.25	67.85	52.67	33.80	51.78
Payable days	115.96	213.72	244.06	149.82	111.46
Cash Conversion Cycle	-6.65	-56.72	-145.98	-82.46	-19.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.